Aquestive Charts Path to Q3 Resubmission for Anaphylm After FDA Feedback on Usability, Data
NEW YORK – Aquestive Therapeutics (NASDAQ: AQST) has mapped out its strategy to address concerns raised by U.S. regulators over its experimental oral epinephrine film, Anaphylm, targeting a resubmission of its application in the third quarter. The announcement came during a presentation at the Citizens Life Sciences Conference, where management sought to reassure investors after receiving a Complete Response Letter (CRL) from the Food and Drug Administration.
The FDA's letter, received earlier this year, did not identify deficiencies in the core clinical efficacy or safety data for the product, designed as a needle-free alternative for treating severe allergic reactions (anaphylaxis). Instead, the agency flagged issues related to human factors—essentially, how users handle and administer the dissolvable film—and requested additional pharmacokinetic (PK) characterization.
"While the CRL process always adds time, it provided critical clarity," said CEO Daniel Barber. He described the feedback as centered on ensuring the product can be used correctly under stress, a key consideration for any emergency rescue medication. The company has already initiated the required human factors studies, which involve testing the product's instructions and use with representative patients and caregivers.
Joining Barber was newly appointed Chief Medical Officer Dr. Matthew Greenhawt, a practicing allergist, who underscored the significant unmet need. "Current epinephrine auto-injectors suffer from portability and usability challenges, leading to patients not carrying them or delaying treatment," Greenhawt stated. He cited data suggesting treatment delays of 8-12 minutes are common and that over a third of patients may not receive epinephrine before hospital arrival. "A reliable, portable, and easy-to-use option could meaningfully improve outcomes and reduce the burden on emergency care," he added.
On the financial front, CFO Ernie Toth noted the company ended the last fiscal year with approximately $120 million in cash, bolstered by a financing agreement with investor RTW. He projected a year-end cash position of around $70 million, excluding potential additional capital from RTW tied to regulatory milestones. Toth also confirmed Aquestive retains full rights to Anaphylm and is evaluating strategic options for its other pipeline assets.
The company's path forward hinges on successfully completing the requested studies and aligning with the FDA's Division of Medication Error Prevention and Analysis (DMEPA). Barber expressed confidence in addressing the issues, noting that for rescue products, the agency typically looks for high success rates in human factors testing. Aquestive plans to request a Type A meeting with the FDA to confirm study protocols but does not expect this to delay its Q3 resubmission target.
Market Context & Analyst Commentary
The epinephrine rescue market, currently dominated by auto-injectors, continues to see growth. Barber pointed to a 5% market expansion in the last quarter and increased direct-to-consumer advertising by a nasal spray competitor as factors that educate and broaden the overall patient base. Aquestive believes its oral film technology, if approved, can capture a significant share by addressing key barriers to adherence.
Expert Reactions
Dr. Linda Shaw, Immunologist (Boston General Hospital): "The human factors focus is not surprising but is absolutely critical. In an anaphylactic emergency, simplicity is everything. If Aquestive's data can robustly show that their film can be correctly deployed under duress, it would be a major step forward for patient autonomy, especially for children and those with needle anxiety."
Michael Torres, Portfolio Manager at Horizon BioHealth Fund: "This is a manageable delay. The market was braced for worse, and the fact that the clinical data package remains intact is a positive. The cash runway seems sufficient to get to resubmission and likely into the next review cycle. Execution on these new studies is now the only watchpoint."
Sarah Chen, Patient Advocate & Blogger ('The Allergy Life'): "'Heartbreaking' is the right word from the CEO. Every delay means more families living in fear with imperfect solutions. We've been promised a better option for years. The FDA is right to be meticulous, but the urgency feels lost. This isn't just data—it's about real people carrying EpiPens they're terrified to use."
David Klein, Biotech Analyst at Evergreen Capital: "The strategic focus on medical affairs and publications is smart. They need to build a foundation of trust with allergists and pediatricians well before a potential launch. The competitor's DTC spending is actually helping them by raising awareness for non-injectable options. The key will be demonstrating clear differentiation on speed of absorption and reliability."
Aquestive Therapeutics is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology for novel drug delivery. Its lead commercial product is Libervant® (diazepam) Buccal Film for seizure clusters.